SLC7A5 and breast carcinoma: Among these, a Chinese patent elucidates a detection kit for detecting postoperative breast cancer recurrence and metastasis involving SLC50A1, thus introducing SLC50A1 as a biomarker for identifying postoperative recurrence or metastasis in breast cancer cases [15]; a New Zealand patent divulges various early diagnostic markers for breast cancer, including SLC1A5 and SLC7A5 [16].